12D7

12D7 is a human monoclonal antibody that targets the Cancer/Testis (CT) antigen NY-ESO-1 (also known as Cancer/testis antigen 1B). It was developed to enhance tumor-specific immunity by forming immune complexes with NY-ESO-1 antigens released from tumor cells, particularly following treatments like chemotherapy that induce immunogenic cell death. These immune complexes are efficiently captured by dendritic cells and cross-presented to CD8+ T cells, thereby stimulating a targeted cytotoxic T-lymphocyte response against NY-ESO-1-expressing tumors. Preclinical studies have demonstrated that 12D7 significantly improves the efficacy of chemotherapy, such as 5-fluorouracil, in syngeneic tumor models. In addition to its development as a therapeutic agent, the name 12D7 is also widely used to refer to a CD4+ human T-leukemic cell line (a subclone of the CEM line) used in HIV and multidrug resistance research, and the antibody clone itself is frequently employed as a non-reactive isotype control in various immunological assays.

Other names

anti-NY-ESO-1 human monoclonal antibody 12D7anti-NY-ESO1 human monoclonal antibody 12D7anti-NY-ESO 1 human monoclonal antibody 12D7